Patent ID: 8663695
Filing Date: 2014-03-04
Classification: A61K,A61L,A61P

Abstract:
1. A nasal formulation for the treatment of fungus-induced rhinosinusitis comprising an aqueous suspension of steroidal anti-inflammatory particles, said suspended solid steroidal anti-inflammatory particles comprising beclomethasone dipropionate monohydrate equivalent to 0.042% w/w beclomethasone dipropionate and having the following particle size distribution profile: (i) about 10% or less of the steroidal anti-inflammatory particles have a particle size of less than 0.3 microns; (ii) about 25% or less of the steroidal anti-inflammatory particles have a particle size of less than 0.55 microns; (iii) about 50% or less of the steroidal anti-inflammatory particles have a particle size of less than 1.1 microns; (iv) about 75% or less of the steroidal anti-inflammatory particles have a particle size of less than 1.8 microns; and (v) about 90% or less of the steroidal anti-inflammatory particles have a particle size of less than 2.7 microns; and wherein the formulation is suitable for administration to the nasal-paranasal mucosa and said formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 80% of the beclomethasone originally present in the formulation still remains in the formulation.